Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AMY2A | P04746 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095371 | 1.00 | TYR (0.49) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL12563490 | 0.92 | TYR (0.56) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL12604931 | 0.92 | TYR (0.56) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL12563491 | 0.92 | TYR (0.56) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL12902015 | 0.92 | TYR (0.56) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL12901988 | 0.92 | TYR (0.56) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL10047647 | 0.87 | TYR (0.48) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL17341181 | 0.87 | TYR (0.48) | TYRLGALS8LGALS3LGALS4AMY1A | |
| SCHEMBL15144318 | 0.86 | AMY2A (0.52) | LGALS8LGALS3LGALS4AMY1AMEN1 | |
| SCHEMBL13026650 | 0.85 | TYR (0.48) | TYRLGALS8LGALS3LGALS4AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481696-B2 | Glycosylated glycopeptide antibiotic derivatives | SHIONOGI & CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | CSGALNACT1, OGT, GALNT1 | TYR 3454/4885LGALS8 400/4885LGALS3 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.